Gene expression associated with vaginal bleeding in women using the 52-mg levonorgestrel hormonal intrauterine device: A prospective study.
Flávia R TorelliRaquel M Rodrigues-PeresIscia Lopes-CendesLuis BahamondesCassia Raquel Teatin JuliatoPublished in: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2024)
Users of the 52-mg hormonal IUD with elevated relative CXCL9 expression face an increased risk of vaginal bleeding at 3-month follow up, whereas those with heightened TIMP1 expression are more likely to experience vaginal bleeding at 12 months.